



AREN11.US12.CON

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: **Chen W. Liaw et al.**

Confirmation No.: **5835**

Serial No.: **10/782,596**

Art Unit No.: **1646**

Filing Date: **February 19, 2004**

Examiner: **Ruixiang Li**

For: **NUCLEIC ACID ENCODING HUMAN G PROTEIN-COUPLED RECEPTOR**

Customer No.: **35133**

VIA EXPRESS MAIL LABEL NO: EV882773536US  
DATE SENT: September 27, 2006

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

**This Supplemental Information Disclosure Statement is being filed:**

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- ☐ before the mailing date of a first Office Action on the merits.

- ☒ **after** the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
- or**
- ☒ the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
- ☐ No fee is owed by the applicant(s).
- ☐ In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- ☐ **after** the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- ☒ Copies of the references listed on the attached PTO Form SB/08b, formerly known as PTO Form 1449, are enclosed.

**EXCEPT THAT:**

- ☐ In view of the voluminous nature of reference \_\_\_\_, and the likelihood that this reference is available to the Examiner, a copy is not enclosed herewith.
- ☐ In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.

- ☐ If the foregoing publication is not available to the Examiner, Applicant will endeavor to supply a copy at the Examiner's request.

**Statement under 37 C.F.R. § 1.97(e)**

- ☐ The undersigned attorney hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

**Fees**

- ☐ No Fee is owed by the applicant(s).
- ☒ The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

**Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$\_\_\_\_\_. This form is submitted in duplicate.
- ☒ Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
- ☒ Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
- ☐ No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Michael A. Patané  
Registration No. 42,982

Dated: September 27, 2006

COZEN O'CONNOR, P.C.  
1900 Market Street, 5<sup>th</sup> Floor  
Philadelphia, PA 19103-3508  
(215) 665-2000 - Telephone  
(215) 665-2013 - Facsimile



PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/782,596
Filing Date	February 19, 2006
First Named Inventor	Chen Liaw
Art Unit	1646
Examiner Name	Ruixiang Li
Attorney Docket Number	AREN11.US12.CON

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	Barker et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>Journal of Biological Chemistry</i> (1994) 269(16):11687-11690.	
	2	Blaszczyk "Motor deficiency in Parkinson's disease," <i>Acta Neurobiol Exp</i> (1998) 58:79-93.	
	3	Fischman et al., "Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters," <i>Synapse</i> (1998) 29(2):128-141.	
	4	Karpe et al., "The nicotinic acid receptor--a new mechanism for an old drug," <i>The Lancet</i> (2004) 363(9424):1892-1894.	
	5	Leenders et al., "The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease," <i>Arch Neurol</i> (1990) 47(12):1290-1298.	
	6	Montastruc et al., "New directions in the drug treatment of Parkinson's disease," <i>Drugs &amp; Aging</i> (1996) 9(3):169-184.	
	7	Probst et al., "Sequence alignment of the G-protein coupled receptor superfamily," <i>DNA and Cell Biology</i> (1992) 11(1):1-20.	
	8	Ren et al., "Constitutively active mutants of the alpha 2-adrenergic receptor," <i>Journal of Biological Chemistry</i> (1993) 268(22):16483-16487.	
	9	Sonnhammer et al., "A hidden Markov model for predicting transmembrane helices in protein sequences," J. Glasgow et al., eds., <i>Proc. Sixth Int. Conf. on Intelligent Systems for Molecular Biology</i> , pp. 175-182, AAAI Press (1998).	
	10	Zadina et al., "Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density," <i>Annals New York Academy of Sciences</i> (1999) 897:136-144.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.